AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23670746 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloMEM™
Number of subjects: 10
Study 23670876 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients developing synechiae after ESS
Number of subjects: 286
Study 23670876 — intervention group
Group type: COMPARATOR
Intervention: Patients without synechiae after ESS
Number of subjects: 286
Study 23672400 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor stimulation threshold (MTS) TENS
Number of subjects: 60
Study 23672400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation threshold (STS) TENS
Number of subjects: 60
Study 23672400 — intervention group
Group type: COMPARATOR
Intervention: Untreatment
Number of subjects: 60
Study 23674398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin therapy (atorvastatin 80 mg)
Number of subjects: 10001
Study 23674398 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose statin therapy (atorvastatin 10 mg)
Number of subjects: 10001
Study 23674398 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictions
Number of subjects: 10001
Study 23674398 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based treatment decisions
Number of subjects: 10001
Study 23675423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 574
Study 23675423 — intervention group
Group type: COMPARATOR
Intervention: Control group (without MMC)
Number of subjects: 574
Study 23675433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-mental ultrasonography (US)
Number of subjects: 105
Study 23675433 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model using RP diameters at Müller maneuver (MM) and neck circumference
Number of subjects: 105
Study 23675632 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% miconazole nitrate ointment (7-day course)
Number of subjects: 168
Study 23676114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin for at least 5 days, optionally followed by oral voriconazole
Number of subjects: 43
Study 23676114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin
Number of subjects: 43
Study 23676114 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin and voriconazole
Number of subjects: 43
Study 23676198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (subanesthetic dose)
Number of subjects: 10
Study 23676418 — intervention group
Group type: EXPERIMENTAL
Intervention: RET kinase inhibitors
Number of subjects: 26
Study 23676496 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARβ/δ activation
Number of subjects: 0
Study 23676496 — intervention group
Group type: COMPARATOR
Intervention: PPARα overexpression
Number of subjects: 0
Study 23676799 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-empowerment group treatment
Number of subjects: 0
Study 23676799 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy and medical examinations
Number of subjects: 0
Study 23678005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent imatinib (IM) therapy for 1 month on and 1 month off
Number of subjects: 76
Study 23678006 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 1
Study 23678006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor-directed therapy)
Number of subjects: 1
Study 23678376 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (50 mg in an excipient solution applied as a spray to the oropharynx)
Number of subjects: 0
Study 23678376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taste excipients solution without active substance)
Number of subjects: 0
Study 23679960 — intervention group
Group type: EXPERIMENTAL
Intervention: High social desirability scores
Number of subjects: 450
Study 23679960 — intervention group
Group type: EXPERIMENTAL
Intervention: High percentage of meals eaten at home
Number of subjects: 450
Study 23679960 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration equations with psychosocial and diet behavior variables
Number of subjects: 450
Study 23679960 — intervention group
Group type: COMPARATOR
Intervention: Calibration equations without psychosocial and diet behavior variables
Number of subjects: 450
Study 23680407 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 121
Study 23680407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SMT-MS and WLC)
Number of subjects: 121
Study 23680407 — intervention group
Group type: EXPERIMENTAL
Intervention: None specified
Number of subjects: 121
Study 23680457 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (20 g/d for 5 d followed by 5 g/d throughout the trial)
Number of subjects: 0
Study 23680457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23680957 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioJet® rheolytic thrombectomy (RT)
Number of subjects: 10
Study 23680957 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic agents administered during or after the procedure
Number of subjects: 10
Study 23680957 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors after AngioJet® RT
Number of subjects: 10
Study 23681782 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1, 4, 10, or 20 mg/kg doses
Number of subjects: 1603
Study 23682558 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-transforming growth factor-β therapy
Number of subjects: 0
Study 23683550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (carboplatin+doxorubicin alternating with cisplatin; seven preoperative, three postoperative cycles)
Number of subjects: 62
Study 23683550 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery followed by chemotherapy as indicated
Number of subjects: 62
Study 23683550 — intervention group
Group type: COMPARATOR
Intervention: FL-HCC
Number of subjects: 62
Study 23683550 — intervention group
Group type: COMPARATOR
Intervention: HCC
Number of subjects: 62
Study 23683550 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection or orthotopic liver transplantation
Number of subjects: 62
Study 23684512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ldlr(-/-)/Apoa1(+/-) mice
Number of subjects: 49
Study 23684512 — intervention group
Group type: EXPERIMENTAL
Intervention: Native LDL
Number of subjects: 49
Study 23684512 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted HDL
Number of subjects: 49
Study 23684512 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with lowest HDL-C levels
Number of subjects: 49
Study 23684512 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C levels
Number of subjects: 49
Study 23684555 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 150 g portions of farmed salmon per week
Number of subjects: 123
Study 23684555 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 123
Study 23685546 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1360707 (novel triple reuptake inhibitor)
Number of subjects: 0
Study 23686466 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab after drug withdrawal and retreatment
Number of subjects: 0
Study 23687088 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-H6 expression on circulating proinflammatory CD14(+)CD16(+) monocytes in sepsis conditions
Number of subjects: 0
Study 23687088 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble B7-H6 (sB7-H6) detected in sera
Number of subjects: 0
Study 23687088 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-H6 induction in vitro by Toll-like receptor ligands or proinflammatory cytokines
Number of subjects: 0
Study 23687088 — intervention group
Group type: EXPERIMENTAL
Intervention: Production of soluble B7-H6 by activated monocytes and neutrophils
Number of subjects: 0
Study 23687104 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training + weight loss (AEX + WL)
Number of subjects: 33
Study 23687104 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 33
Study 23687572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Number of subjects: 374
Study 23687572 — intervention group
Group type: COMPARATOR
Intervention: 0.25-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Number of subjects: 374
Study 23687598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclip before polypectomy (HC)
Number of subjects: 98
Study 23687598 — intervention group
Group type: COMPARATOR
Intervention: Standard polypectomy (SP)
Number of subjects: 98
Study 23687598 — intervention group
Group type: COMPARATOR
Intervention: Standard polypectomy patients who refused to participate (R)
Number of subjects: 98
Study 23687606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclip before polypectomy (HC)
Number of subjects: 98
Study 23687606 — intervention group
Group type: COMPARATOR
Intervention: Standard polypectomy (SP)
Number of subjects: 98
Study 23687606 — intervention group
Group type: COMPARATOR
Intervention: Standard polypectomy patients who refused to participate (R)
Number of subjects: 98
Study 23688169 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 400 ug twice daily for twelve weeks
Number of subjects: 43
Study 23688169 — intervention group
Group type: COMPARATOR
Intervention: Histamine challenge
Number of subjects: 43
Study 23688169 — intervention group
Group type: COMPARATOR
Intervention: Baseline nitric oxide level
Number of subjects: 43
Study 23688169 — intervention group
Group type: COMPARATOR
Intervention: Saline test
Number of subjects: 43
Study 23688929 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 23688929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound pyrexia
Number of subjects: 0
Study 23688929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23688934 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY (bioabsorbable polymer everolimus-eluting stent)
Number of subjects: 291
Study 23688934 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY ½ dose
Number of subjects: 291
Study 23688934 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element (durable polymer everolimus-eluting stent)
Number of subjects: 291
Study 23688934 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 291
Study 23688934 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element
Number of subjects: 291
Study 23689058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pituitary imaging abnormalities (n = 1,071)
Number of subjects: 8230
Study 23689058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with structural abnormalities (n = 1,071)
Number of subjects: 8230
Study 23689058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with the triad [ectopic posterior pituitary (EPP), pituitary aplasia/hypoplasia and stalk defects] (n not specified)
Number of subjects: 8230
Study 23689058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SOD (n not specified)
Number of subjects: 8230
Study 23689058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with EPP, pituitary hypoplasia, stalk defects, and triad categories (n not specified)
Number of subjects: 8230
Study 23689927 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based pharmacist care
Number of subjects: 0
Study 23689994 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival Palomid 529 (1.9 mg)
Number of subjects: 5
Study 23690312 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocalcemic hyperparathyroidism identified in MrOS (9 subjects, prevalence 0.4%)
Number of subjects: 5814
Study 23690312 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocalcemic hypoparathyroidism identified in MrOS (26 subjects, prevalence 1.1%)
Number of subjects: 5814
Study 23690312 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocalcemic hyperparathyroidism identified in DHS (108 subjects, prevalence 3.1%)
Number of subjects: 5814
Study 23690312 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocalcemic hypoparathyroidism identified in DHS (68 subjects, prevalence 1.9%)
Number of subjects: 5814
Study 23690359 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Number of subjects: 1042
Study 23690359 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires
Number of subjects: 1042
Study 23690417 — intervention group
Group type: EXPERIMENTAL
Intervention: ASXL1 mutations
Number of subjects: 312
Study 23690417 — intervention group
Group type: EXPERIMENTAL
Intervention: SRSF2 mutations
Number of subjects: 312
Study 23690417 — intervention group
Group type: EXPERIMENTAL
Intervention: CBL mutations
Number of subjects: 312
Study 23690417 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH2 mutations
Number of subjects: 312
Study 23690417 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-parameter prognostic score (ASXL1 status, age, hemoglobin, WBC, platelet counts)
Number of subjects: 312
Study 23690417 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent cohort validation of the prognostic score
Number of subjects: 312
Study 23692170 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC5B promoter polymorphism (rs35705950)
Number of subjects: 2633
Study 23692499 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Claudication Questionnaire (ECQ)
Number of subjects: 2235
Study 23692499 — intervention group
Group type: COMPARATOR
Intervention: Ankle-brachial index (ABI)
Number of subjects: 2235
Study 23692499 — intervention group
Group type: COMPARATOR
Intervention: Diabetes status
Number of subjects: 2235
Study 23692690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive foot-worn biomechanical device (AposTherapy) used daily during regular activities
Number of subjects: 19
Study 23692811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Response (MR)
Number of subjects: 290
Study 23692811 — intervention group
Group type: COMPARATOR
Intervention: Homogeneous Response (HR)
Number of subjects: 290
Study 23692811 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Response (PR)
Number of subjects: 290
Study 23692811 — intervention group
Group type: EXPERIMENTAL
Intervention: True Mixed Response (TMR)
Number of subjects: 290
Study 23692856 — intervention group
Group type: EXPERIMENTAL
Intervention: ofatumumab-ICE
Number of subjects: 61
Study 23692856 — intervention group
Group type: EXPERIMENTAL
Intervention: ofatumumab-DHAP
Number of subjects: 61
Study 23692896 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care recording of acute myocardial infarction
Number of subjects: 21482
Study 23692896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admissions recording of acute myocardial infarction
Number of subjects: 21482
Study 23692896 — intervention group
Group type: COMPARATOR
Intervention: All sources combined (primary care, hospital admissions, disease registry)
Number of subjects: 21482
Study 23693065 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed procedure for controlling false discovery rates (FDR) in factorial experiments
Number of subjects: 0
Study 23694831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of OKA/GSK varicella vaccine
Number of subjects: 432
Study 23694831 — intervention group
Group type: EXPERIMENTAL
Intervention: Any varicella vaccine (including OKA/GSK, OKA/Merck, MMR-OKA/GSK)
Number of subjects: 432
Study 23694831 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated cases
Number of subjects: 432
Study 23694948 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 205
Study 23694948 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON Gold In-Tube (QGIT)
Number of subjects: 205
Study 23694948 — intervention group
Group type: COMPARATOR
Intervention: TST (tuberculin skin test)
Number of subjects: 205
Study 23694966 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD leads (Fidelis and non-Fidelis)
Number of subjects: 878
Study 23694966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelis leads
Number of subjects: 878
Study 23694966 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced extraction techniques
Number of subjects: 878
Study 23694966 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger implantation age
Number of subjects: 878
Study 23695823 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE lesions
Number of subjects: 60
Study 23697561 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 302
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (diagnosed via ICD10 codes and rapid tests)
Number of subjects: 13767
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired rotavirus gastroenteritis
Number of subjects: 13767
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired rotavirus gastroenteritis
Number of subjects: 13767
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence rate of hospital-acquired rotavirus gastroenteritis
Number of subjects: 13767
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization duration for community-acquired rotavirus gastroenteritis
Number of subjects: 13767
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization duration for all rotavirus gastroenteritis cases
Number of subjects: 13767
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of hospital-acquired rotavirus gastroenteritis in children aged below 18 months
Number of subjects: 13767
Study 23697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of hospital-acquired rotavirus gastroenteritis in children hospitalized for at least 5 days
Number of subjects: 13767
Study 23697706 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet for 2 months
Number of subjects: 98
Study 23697705 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) concentrations <10 ng/mL
Number of subjects: 240
Study 23697705 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥10 to <20 ng/mL
Number of subjects: 240
Study 23697705 — intervention group
Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥20 ng/mL (highest category)
Number of subjects: 240
Study 23697705 — intervention group
Group type: COMPARATOR
Intervention: Serum concentrations of 25(OH)D
Number of subjects: 240
Study 23698253 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 15 mg IV weekly and Pazopanib 400 mg orally daily
Number of subjects: 7
Study 23698253 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 10 mg IV weekly and Pazopanib 200 mg orally daily
Number of subjects: 7
Study 23698253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of temsirolimus and pazopanib
Number of subjects: 7
Study 23700789 — intervention group
Group type: COMPARATOR
Intervention: L-NAME 0 mg.kg-1 (Control)
Number of subjects: 27
Study 23700789 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg.kg-1
Number of subjects: 27
Study 23700789 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME 2 mg.kg-1
Number of subjects: 27
Study 23700789 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME 4 mg.kg-1
Number of subjects: 27
Study 23701810 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment (antidepressants, anticonvulsants, opiates)
Number of subjects: 84
Study 23701810 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with 5% lidocaine medicated plaster
Number of subjects: 84
Study 23701891 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive-affective therapy (ICAT)
Number of subjects: 80
Study 23701891 — intervention group
Group type: COMPARATOR
Intervention: Enhanced cognitive-behavioral therapy (CBT-E)
Number of subjects: 80
Study 23701891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICAT and CBT-E
Number of subjects: 80
Study 23702009 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Number of subjects: 405
Study 23702009 — intervention group
Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 405
Study 23702951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension intervention via telemedicine
Number of subjects: 0
Study 23702951 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 23703107 — intervention group
Group type: EXPERIMENTAL
Intervention: LA expansion index (calculated as (Volmax - Volmin) × 100%/Volmin)
Number of subjects: 1735
Study 23703107 — intervention group
Group type: EXPERIMENTAL
Intervention: LA expansion index
Number of subjects: 1735
Study 23703364 — intervention group
Group type: EXPERIMENTAL
Intervention: WiCS(®)-LV system (leadless pacing system)
Number of subjects: 3
Study 23703448 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially covered SEMS (Group A)
Number of subjects: 55
Study 23703448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered SEMS with fins (Group B)
Number of subjects: 55
Study 23703448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered SEMS with flared ends (Group C)
Number of subjects: 55
Study 23703448 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEMS (all groups combined)
Number of subjects: 55
Study 23703580 — intervention group
Group type: EXPERIMENTAL
Intervention: GFT505
Number of subjects: 0
Study 23703638 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted wound closure and mesh-mediated fascial traction (VAWCM)
Number of subjects: 111
Study 23703723 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (exercise, behavior, and nutrition therapy)
Number of subjects: 40
Study 23703723 — intervention group
Group type: COMPARATOR
Intervention: Obese children without weight loss
Number of subjects: 40
Study 23703723 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 40
Study 23703925 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 205
Study 23703925 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspiration thrombectomy)
Number of subjects: 205
Study 23704672 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 699
Study 23704672 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 699